The gut microbiota’s impact on the onset of metabolic complications like obesity and diabetes, and neuropsychiatric disorders like autism has been widely described. However, fewer studies have been conducted on the involvement of the different microbiota in the susceptibility to and development of infectious diseases, although they represent an important field of research. Recent publications have, however, highlighted the gut microbiota’s role on the susceptibility to and severity of lung infections with Mycobacterium TuberculosisE. Moreover, several authors are investigating modulation of vaccine response by the gut microbiota, particularly with respect to oral vaccines. Antibiotics are also likely to have a significant impact on the dialogue between pathogens and commensal flora. The interactions between HIV infection and the gut microbiota represent a very specific field, and the impact of digestive immunity on the disease's development at the chronic phase has been known for many years. Given its impact on the virus’ transmission, analysis of the gut microbiota was naturally followed by analysis of the vaginal microbiota, And the studies have produced some compelling results. Here, as in other pathological situations, the question of how this microbiota could be modulated to impact the disease's development/acquisition is now being investigated, specifically by analysing the eating habits of a population of patients in which the obesity rate is steadily rising, as it is in the general population.
Microbiota and HIV/AIDS
Editoral
Table of contents
Special Report
- Microbiota and HIV/AIDSContributors :
- Microbiota and HIV/AIDS
Interview
- Charles CazanaveContributors :
- Charles Cazanave
In Brief
Microbiota News
- The thanatobiota, for more accurate determination of the post-mortem interval?Scientific committee : Stanislas Bruley des Varannes
- The thanatobiota, for more accurate determination of the post-mortem interval?
The Microbiota Chronicle
- Restoring the gut microbiota: a therapeutic challenge in MSScientific committee : Patrick Vermersch
- ‘Aged’ gut microbiota induces sex-dependent hepatic inflammation and insulin resistanceScientific committee : Philippe Gérard
- Anal cancer induced by HPV and gut dysbiosisScientific committee : Jean-Marc Bohbot
- Surveillance rate for Barrett's oesophagus: to be defined by gut microbiota monitoring?Scientific committee : Stanislas Bruley des Varannes
- Impact of human milk oligosaccharides on the gut microbiotaScientific committee : Bruno Pot
- Restoring the gut microbiota: a therapeutic challenge in MS
Focus
- GastroenterologyScientific committee : Stanislas Bruley des Varannes, Jacques Amar
- Metabolism - ObesityScientific committee : Philippe Gérard
- ImmunologyScientific committee : Cyrille Hoarau
- NeonatologyScientific committee : Bruno Pot
- PulmonologyScientific committee : Geneviève Héry-Arnaud
- Gastroenterology
Taxonomic Reference
Scientific committee
Pr Geneviève Héry-Arnaud
PharmD, PhD. Microbiologist, INSERM Mixed Research Unit 1078, Brest University, Brest Regional and University Hospital
Pr Bruno Pot
PhD, Microbiologist, Brussels University
Pr Patrick Vermersch
MD, PhD. Neurologist, Lille University, Lille
Pr Jacques Amar
MD. Cardiologist, Toulouse University Hospital, Vaiomer scientific consultant, Labège.
Dr Jean-Marc Bohbot
MD, PhD. Infectious disease specialist, Institut Alfred Fournier, Paris
Pr Stanislas Bruley des Varannes
MD, PhD. Gastroenterologist, Digestive Diseases Institute, Nantes
Dr Philippe Gérard
PhD. Microbiologist, Micalis Institute, Jouy-en-Josas
Dr Cyrille Hoarau
MD, PhD. Immunologist and allergy specialist, Interdisciplinary Unit of Clinical Immunology and Allergy Studies, Regional and University Hospital, Tours